Antibacterial agents

• US 20030180319A1
• Filed: 08/07/2002
• Published: 09/25/2003
• Est. Priority Date: 03/25/2002
• Status: Abandoned Application

• Current Assignee: Novolytics Limited (Innoviva, Inc.)
• Original Assignee: Novolytics Limited (Innoviva, Inc.)
• Inventors: Glancey, Liudmilla Pencheva, Mann, Nicholas Harold, Burden, Faith Adelaide, Rapson, Mark Edward, Hodgson, David Allan
• Application Number:
  US10/215,056
• Publication Number:
  US 20030180319A1
• Time in Patent Office: Days
• US Class Current: 424/199.1
• CPC Class Codes: A01N 63/40 Viruses, e.g. bacteriophages
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 45/00 Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/70 involving virus or bacteriophage immunoassay for viruses G01N33/56983

Abstract

A panel of bacteriophages having a first vir mutant bacteriophage capable of infecting and lysing a first strain of bacteria, and a second vir mutant capable of infecting and lysing a second strain of bacteria. A pharmaceutical composition including a panel of bacteriophages disclosed above. A method of identifying a bacteriophage suitable for killing a bacterium by obtaining a sample of the bacterium from a patient or site infected with the bacterium, identifying one or more phage sensitivity characteristics of the bacterium, comparing the characteristics from the identification step with the known host range of each library of bacteriophages, the library of bateriophages including a first vir mutant bacteriophage capable of infecting and lysing a first strain of bacteria, and a second vir mutant capable of infecting and lysing a second strain of bacteria, and identifying one or more bacteriophages from the panel suitable for killing the bacterium.

Claims

1. A panel of bacteriophages comprising a first vir mutant bacteriophage capable of infecting and lysing a first strain of bacteria, aid a second vir mutant capable of infecting and lysing a second strain of bacteria.

2. A panel according to claim 1, wherein each said strain of bacteria is a human or animal or plant pathogen.

3. A panel according to claim 1 comprising different bacteriophages.

4. A panel according to claim 1 comprising at least one host rage change mutant bacteriophage.

5. A panel according to claim 1 wherein at least one of the said strains of bacteria is resistant to one or more antibiotics.

6. A pharmaceutical composition comprising a panel of bacteriophages according to claim 1, in combination with a pharmaceutically acceptable carrier.

7. A pharmaceutical composition according to claim 6, adapted for topical application.

8. A pharmaceutical composition according to claim 6 for use as a medicament.

9. Use of a pharmaceutical composition according to claim 6 for prophylaxis.

10. An antibacterial composition comprising a panel of bacteriophages according to claim 1, in combination with a carrier.

11. Use of an antibacterial composition according to claim 10 as a disinfectant.

12. Use of an antibacterial composition according to claim 10 as an antiseptic.

13. Use of an antibacterial composition according to claim 10 as a constituent of a surgical or medical device.

17. A machine readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the data defines one or more characteristics of each bacteriophage in a panel of bacteriophages as defined in claim 1.

19. A method of producing a panel according to claim 1, comprising cultivating a donor bacterium, identify one or more temperate bacteriophages from said donor bacterium, mutating the temperate bacteriophages and isolating one or more vir mutants of said bacteriophages.

20. A method of producing a panel according to claim 19, comprising the steps of:

(i) isolating said first, donor, bacterium;

(ii) co-culturing said first bacterium with a second, cultivating, strain of bacterium capable of being infected with bacteriophage;

(iii) identifying temperate bacteriophages obtained from said first, donor, bacterium;

(iv) mutating said temperate bacteriophages identified in step (iii) with a mutagen; and

(v) cultivating said first, donor, bacterium with the mutated bacteriophage from step (iv) to identify vir mutants capable of lysing said first, done, bacterium.

21. A method of producing a panel according to claim 19, comprising the steps of:

(i) isolating said first, donor, bacterium;

(ii) inducing said donor bacterium to produce temperate bacteriophages with a chemical or physical agent;

(iii) identifying temperate bacteriophages obtained from the first, donor, bacterium;

(iv) mutating said temperate bacteriophages identified in step (iii) with a mutagen; and

(v) cultivating said first, donor, bacterium with the mutated bacteriophage from step (iv) to identify vir mutants capable of lysing said first, donor, bacterium.

22. A method of producing a panel of bacteriophages according to claim 1, comprising:

(i) isolating a first, donor, bacterium of interest;

(ii) co-culturing the first bacterium with a second, cultivating strain of bacterium capable of being infected with bacteriophage;

(iii) identifying one or more temperate bacteriophages obtained front said first, donor bacterium;

(iv) mutating said temperate bacteriophages identified in step (iii) with a mutagen; and

(v) cultivating the mutated temperate bacteriophages obtained from step (iv), with a third strain of bacterium previously not infected with the bacteriophage, to identify one or more host range change bacteriophages.

23. A method of producing a panel of bacteriophages according to claim 1, comprising:

(i) isolating a first, donor, bacterium of interest;

(ii) inducing said donor bacterium to produce temperate bacteriophages with a chemical or physical agent;

(iii) identifying one or more temperate bacteriophages obtained from said first, donor, bacterium;

(iv) mutating said temperate bacteriophages identified in step (iii) with a mutagen; and

(v) cultivating the mutated temperate bacteriophages obtained from step (iv), with a third strain of bacterium previously not infected with the bacteriophage, to identify one or more host range change bacteriophages.

27. A panel according to claim 1, comprising a vir mutant identified by a method according to claim 24.

14. A method of identifying a bacteriophage suitable for killing a bacterium, comprising the steps of:

(i) obtaining a sample of said bacterium from patient or place infected with said bacterium;

(ii) identifying one or more phage sensitivity characteristics of said bacterium;

(iii) comparing the characteristics from step (ii) with the known host range of each bacteriophage of a library of bacteriophages said library of bacteriophages comprising a first vir mutant bacteriophage capable of infecting and lysing a first strain of bacteria, and a second vir mutant capable of infecting and lysing a second strain of bacteria; and

(iv) identifying one or more bacteriophages from the panel suitable for killing said bacterium.

15. A method according to claim 14, wherein the presence or absence of one or more prophages in said bacterium is determined by PCR using a pair of primers to amplify the prophage DNA from said bacterium.

18. A machine readable data storage medium, comprising a data storage material encoded with machine readable data, wherein the data defines one or more characteristics of each bacteriophage in a library of bacteriophages as defined in claim 14.

16. A method of identifying the presence of one or more prophages in a bacterium comprising a pair of primers capable of hybridising under high stringency conditions to a prophage nucleotide sequence, and carrying our PCR to identify the presence of said prophage.

24. A method of identifying a bacteriophage for treating an animal or plant infected with a bacterial pathogen, comprising:

(i) isolating said bacterial pathogen;

(ii) isolating a lysogenic bacteriophage from the bacterium; and

(iii) mutating said lysogenic bacteriophage to produce a vir mutant of the lysogenic bacteriophage.

25. A method according to claim 24, wherein the vir mutant is admixed with one or more pharmaceutically acceptable carriers.

26. A method according to claim 24 comprising the step of using said vir mutant identified by the method to treat said bacterial infection.

28. A primer pair for identifying the presence of an integrase gene of a bacteriophage by PCR, comprising nucleotide sequence selected from: